Brian Stevens - Genpact Independent Director
| G Stock | USD 49.44 1.67 3.27% |
Director
Brian Stevens is Independent Director of Genpact Limited since 2020.
| Age | 57 |
| Tenure | 5 years |
| Address | Canon's, Court, Hamilton, Bermuda, HM 12 |
| Phone | (441) 298-3300 |
| Web | https://www.genpact.com |
Brian Stevens Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Stevens against Genpact stock is an integral part of due diligence when investing in Genpact. Brian Stevens insider activity provides valuable insight into whether Genpact is net buyers or sellers over its current business cycle. Note, Genpact insiders must abide by specific rules, including filing SEC forms every time they buy or sell Genpact'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Stevens over six months ago Acquisition by Brian Stevens of 821 shares of Baxter International subject to Rule 16b-3 | ||
Brian Stevens over six months ago Disposition of 545 shares by Brian Stevens of Baxter International at 42.5 subject to Rule 16b-3 |
Genpact Management Efficiency
The company has return on total asset of 0.089 % which means that for every 100 dollars spent on assets, it generated a profit of $0.089. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2215 %, implying that it made 0.2215 on every $100 invested by shareholders. Genpact's management efficiency ratios could be used to measure how well Genpact manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.10. The current Return On Capital Employed is estimated to decrease to 0.10. At this time, Genpact's Non Currrent Assets Other are most likely to increase significantly in the upcoming years. The Genpact's current Intangibles To Total Assets is estimated to increase to 0.45, while Total Assets are projected to decrease to roughly 3.2 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jason Liberty | WNS Holdings | 45 | |
| Brett Keller | Broadridge Financial Solutions | 51 | |
| Robert Bedingfield | Science Applications Internatio | 71 | |
| James Pavitt | CACI International | 74 | |
| William Jews | CACI International | 68 | |
| Steven Shane | Science Applications Internatio | 62 | |
| Mariel Joliet | ASGN Inc | 54 | |
| Charles Revoile | CACI International | 85 | |
| Jonathan Holman | ASGN Inc | 74 | |
| Amit Zavery | Broadridge Financial Solutions | 49 | |
| Thomas Perna | Broadridge Financial Solutions | 68 | |
| Garth Graham | Science Applications Internatio | 45 | |
| John Freeland | WNS Holdings | 65 | |
| Mark Frantz | ASGN Inc | 50 | |
| Francoise Gri | WNS Holdings | 62 | |
| Debora Plunkett | CACI International | 60 | |
| Alan Weber | Broadridge Financial Solutions | 71 | |
| Pamela Carter | Broadridge Financial Solutions | 71 | |
| Robert Duelks | Broadridge Financial Solutions | 65 | |
| Gregory Johnson | CACI International | 74 | |
| Brian Callaghan | ASGN Inc | 49 | |
Management Performance
| Return On Equity | 0.22 | |||
| Return On Asset | 0.089 |
Genpact Limited Leadership Team
Elected by the shareholders, the Genpact's board of directors comprises two types of representatives: Genpact inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genpact. The board's role is to monitor Genpact's management team and ensure that shareholders' interests are well served. Genpact's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genpact's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Piyush Mehta, Chief Human Resources Officer, Senior Vice President | ||
| Edward Fitzpatrick, Chief Financial Officer, Senior Vice President | ||
| CFA CFA, VP CFO | ||
| Carol Lindstrom, Independent Director | ||
| Kathryn Stein, Senior Vice President, Chief Strategy Officer and Global Business Leader, Enterprise Services | ||
| Edward CPA, Senior Advisor | ||
| Sanjay Srivastava, Senior Officer | ||
| Nallicheri Tyagarajan, CEO President | ||
| Krista Bessinger, Head Relations | ||
| Brian Stevens, Independent Director | ||
| Kevin Webb, Head Services | ||
| Sanjeev Vohra, Chief Officer | ||
| Michael CFA, Senior CFO | ||
| Laura Conigliaro, Independent Director | ||
| Tamara Franklin, Independent Director | ||
| Ezra Baylin, Head Acquisitions | ||
| Hailey Eichner, Chief CEO | ||
| CeCelia Morken, Independent Director | ||
| Mark Verdi, Independent Director | ||
| Vipin Gairola, Global Officer | ||
| Darren Saumur, Senior Vice President Global Operating Officer | ||
| Sameer Dewan, Senior Leader | ||
| Patrick Cogny, Senior Vice President - Infrastructure, Manufacturing & Services and High Tech | ||
| Ajay Agrawal, Independent Director | ||
| Michael Weiner, Chief Financial Officer, Senior Vice President | ||
| Roger CFA, Head Relations | ||
| Balkrishan Kalra, Senior Vice President - Banking, Capital Markets, Consumer Goods, Retail, Life Sciences and Healthcare | ||
| Heather White, Senior Vice President, Chief Legal Officer, Corporate Secretary | ||
| Vidya Rao, Chief Officer | ||
| N Tyagarajan, President, Chief Executive Officer, Director | ||
| Anil Nanduru, Consumer Manufacturing | ||
| Stacey Cartwright, Independent Director | ||
| Donald Klunk, Chief Officer | ||
| Rajiv Naidu, Business Affairs | ||
| Mark Nunnelly, Independent Director | ||
| James Madden, Non-Executive Independent Chairman of the Board | ||
| Caitlin Blewett, Chief Officer | ||
| Riju Vashisht, Chief Officer | ||
| Heather JD, Chief VP |
Genpact Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genpact a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | |||
| Return On Asset | 0.089 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 9.75 B | |||
| Shares Outstanding | 175.67 M | |||
| Shares Owned By Insiders | 1.04 % | |||
| Shares Owned By Institutions | 98.96 % | |||
| Number Of Shares Shorted | 4.38 M | |||
| Price To Earning | 28.59 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genpact Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Data Processing & Outsourced Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genpact. If investors know Genpact will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genpact listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.50) | Dividend Share 0.61 | Earnings Share 2.89 | Revenue Per Share | Quarterly Revenue Growth 0.089 |
The market value of Genpact Limited is measured differently than its book value, which is the value of Genpact that is recorded on the company's balance sheet. Investors also form their own opinion of Genpact's value that differs from its market value or its book value, called intrinsic value, which is Genpact's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genpact's market value can be influenced by many factors that don't directly affect Genpact's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genpact's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genpact is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genpact's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.